All In Biotech

Drug Trial Radar · NCT07298343

Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

356

Planned (sponsor's estimate)

Start

Jun 10, 2024

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet

Conditions

  • Celiac Disease

Interventions

  • ZED1227 + SIGEDrug

    oral treatment with different daily doses of ZED1227 vs placebo

  • PlaceboOther

    Placebo + SIGE

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CDSD GI Specific Symptom ScoreTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Mainz

    Mainz, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.